Ç÷¾×ÇÐ
- ÀúÀÚ(±Û)´ëÇÑÇ÷¾×ÇÐȸ °øÀú
- ÃâÆÇ»çE*PUBLIC
- ¹ßÇàÀÏ2006³â 05¿ù 25ÀÏ
35³âÀ» Á־߷ΠȯÀÚ¿Í ÇÔ²²ÇÑ Ç÷¾×¾Ï Ä¡·á Àü¹®°¡
ÁÖ¿ä Áø·á ºÐ¾ß´Â ¹éÇ÷º´, ¸²ÇÁÁ¾, Á¶Ç÷¸ð¼¼Æ÷À̽ÄÀÌ´Ù. °Ç±¹´ëÇб³ Àǰú´ëÇаú º´¿ø¿¡ ±³¼ö·Î ÀçÁ÷ÇÏ¸é¼ º´¿øÀå, ÀÇ·á¿øÀå, Àǹ«ºÎÃÑÀåÀ» ¿ªÀÓÇß´Ù.
´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ÀÌ»çÀåÀ» ¿ªÀÓÇß´Ù. °Ç°º¸Çè½É»çÆò°¡¿ø ºñ»ó±Ù½É»çÀ§¿øÀ¸·Î 15³â µ¿¾È °øÇåÇÏ¿´°í, Çѱ¹Á¶Ç÷¸ð¼¼Æ÷ÀºÇàÇùȸ¿Í Çѱ¹Ç÷¾×¾ÏÇùȸ ÀÌ»ç·Î¼ 20³â °¡±îÀÌ »çȸ°øÇåÀ» ÇÏ¿´´Ù. 2025³â ÇöÀç °Ç±¹´ëÇб³ ¸í¿¹±³¼öÀÌÀÚ °Ç±¹´ëÇб³º´¿ø ÀÚ¹®±³¼ö·Î Áø·áÇϰí ÀÖÀ¸¸ç, 2024³â 3¿ùºÎÅÍ Çѱ¹Á¶Ç÷¸ð¼¼Æ÷ÀºÇàÇùȸ ȸÀåÁ÷À» ¸Ã°í ÀÖ´Ù. 2017³â Á¦ 20ȸ ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ Çмú»ó ´ë»óÀ» ¼ö»óÇß´Ù. 2018³â °Ç°º¸ÇèºÐÀïÁ¶Á¤À§¿øÈ¸ À§¿øÀ¸·Î Ȱµ¿ÇÏ¸é¼ °Ç°º¸Çè Á¦µµ °³¼±¿¡ ±â¿©ÇÑ °øÀ» ÀÎÁ¤¹Þ¾Æ º¸°Çº¹ÁöºÎÀå°ü ǥâÀåÀ» ¼ö»óÇß´Ù.
| Á¦ ¸ñ | Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2024 | ¹ßÇ¥Áö | Haematologica |
| Á¦ ¸ñ | Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2023 | ¹ßÇ¥Áö | Haematologica |
| Á¦ ¸ñ | FDG PET/CT maximum tumor dissemination to predict recurrence in patients with diffuse large B-cell lymphoma | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2023 | ¹ßÇ¥Áö | Nucl Med Mol Imaging |
| Á¦ ¸ñ | Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2021 | ¹ßÇ¥Áö | Korean J Intern Med |
| Á¦ ¸ñ | Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party. | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2019 | ¹ßÇ¥Áö | Ann Hematol |
| Á¦ ¸ñ | Oral mucormycosis in patients with haematologic malignancies in a bone marrow transplant unit | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2017 | ¹ßÇ¥Áö | Mycoses |
| Á¦ ¸ñ | Predictors of general discomfort, limitations in activities of daily living and intention of a second donation in unrelated hematopoietic stem cell donation | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2017 | ¹ßÇ¥Áö | Bone Marrow Transplant |
ÁÖ¿ä °ü½É/Àü¹® ºÐ¾ß´Â Ç÷¾×¾Ï(¹éÇ÷º´, ¸²ÇÁÁ¾) Ä¡·áÀ̸ç, À̸¦ À§Çؼ Ç×¾ÏÈÇпä¹ý°ú ¼¼Æ÷Ä¡·á¹ýÀÇ Àû¿ë°ú ¹ßÀü¿¡ Áö³ 35³â µ¿¾È Àü³äÇϰí ÀÖ´Ù. ±¹Á¦Àû Àü¹®ÇмúÁö¿¡ ¾à 150ÆíÀÇ ³í¹®À» ¹ßÇ¥Çß´Ù.
Àǻ簡 ȯÀÚ Áø·á¿¡ ÀÖ¾î¼ °®Ãß¾î¾ß ÇÒ ´ö¸ñÀº Áø½ÇÇϰí ÂüµÈ Àμº°ú »çȸÀû °øÇå ¸øÁö ¾Ê°Ô Áß¿äÇÑ °ÍÀÌ º¸´Ù ³ªÀº Áúº´ Ä¡·á¸¦ À§Çؼ Ç×»ó ²÷ÀÓ¾øÀÌ Àü¹®Áö½ÄÀ» ÇÔ¾çÇÏ°í ½ÀµæÇÏ´Â °ÍÀÌ´Ù.
ÃÖ¼±ÀÇ Áúº´ Ä¡·á´Â ȯÀÚ, ÀÇ·áÁø, º¸È£ÀÚ°¡ ÇÑÆÀÀÌ µÇ¾î ¼·ÎÀÇ ½Å·Ú ¼Ó¿¡¼, Ä¡·á ¸ñÇ¥ ´Þ¼ºÀ» À§Çؼ ²ÙÁØÈ÷ ³ë·ÂÇÒ ¶§ ÀÌ·ç¾îÁú ¼ö ÀÖ´Ù.

°Ç±¹´ëÇб³º´¿øÀº »óÇã À¯¼®Ã¢ ¼±»ý²²¼ ÀÏÁ¦ °Á¡±âÀÎ 1931³â ¹ÎÁ·ÁöµµÀÚµé°ú ¶æÀ» ¸ð¾Æ ±¸·áÁ¦¹Î(ÏÖûðÚÅ)°ú Àμúº¸±¹(ìÒâúÜÃÏÐ)ÀÇ Å« ¶æÀ» ´ã¾Æ ¼³¸³ÇÑ ¡®»çȸ¿µ Á߾ӽǺñÁø·á¿ø¡¯¿¡ »Ñ¸®¸¦ µÎ°í ÀÖ´Ù. 2002³â °Ç±¹´ëÇб³ ¼¿ïÄ·ÆÛ½º ³²´Ü¿¡ º´¿ø °Ç¹°À» »õ·Î Áþ±â ½ÃÀÛÇØ 2005³â 8¿ù »õ·Ó°Ô žÀ¸¸ç ÁöÇÏ4Ãþ, Áö»ó 13Ãþ ¿¬¸éÀû 2¸¸ 6300¿©ÆòÀÇ »õ °Ç±¹´ëº´¿øÀº 33°³ÀÇ Áø·á°ú¿Í 784°³ÀÇ º´»ó, 9°³ÀÇ ÁßÁ¡¼¾ÅÍ¿Í 14°³ÀÇ Áø·á¼¾ÅÍ, ÇコÄɾÅ͸¦ °®Ãß°í 430¿©¸íÀÇ ÀÇ·áÁøÀÌ Áø·á¸¦ Çϰí ÀÖ´Ù. 2009³â °©»ó¼±¾Ï¼¾ÅÍ, ´ëÀå¾Ï¼¾ÅÍ, À¯¹æ¾Ï¼¾ÅÍ µî ¾Ï¼¾Å͸¦ °³¼³Çϰí, 2017³â 11¿ù¿¡´Â ÃÖ½ÅÇü ·Îº¿ ¸ðµ¨ÀÎ 4¼¼´ë ´ÙºóÄ¡Xi¸¦ µµÀÔ, ·Îº¿¼ö¼ú ¼¾ÅÍ °¡µ¿À» ½ÃÀÛÇß´Ù. °Ç±¹´ëº´¿øÀº ´ëÀå¾Ï, À¯¹æ¾Ï, Æó¾Ï, À§¾Ï, Ç÷¾×Åõ¼®, ¸¸¼ºÆó¼â¼ºÆóÁúȯ µî ÁßÁõÁúȯ ºÐ¾ß Æò°¡¿¡¼ 1µî±ÞÀ» ±â·ÏÇϰí ÀÖÀ¸¸ç, °ñµçŸÀÓÀÌ Áß¿äÇÑ ½ÉÇ÷°üÁúȯ°ú ³úÇ÷°üÁúȯÀÇ ½Å¼ÓÁø·á½Ã½ºÅÛÀ» ¿î¿µÇÏ¸ç ±Þ¼º±â ³úÁ¹Áß ¹× °ü»óµ¿¸Æ¿ìȸ¼ú Æò°¡¿¡¼µµ 1µî±ÞÀ» À̾°í ÀÖ´Ù. Áö³ 2023³â¿¡´Â ÁßÁõÁúȯ Ä¡·á ¿ª·® °È¸¦ À§ÇØ ÁßȯÀÚ½Ç ¹× ¼ö¼ú½Ç Áõ¼³, ·Îº¿¼ö¼ú±â±â Ãß°¡ ¹× CTµî ½ÅÇüÀÇ·áÀåºñ µîÀ» µµÀÔÇß´Ù. À̾î 2024³â¿¡´Â ȯÀÚµéÀÇ ÄèÀûÇÑ È¯°æÀ» À§ÇØ º´µ¿ ȯ°æÀ» °³¼±Çϰí, 2025³â¿¡´Â ¿Ü·¡¼¾ÅÍ ÁõÃàÀ» ¾ÕµÎ°í ÀÖ´Ù.
¼¿ïƯº°½Ã ±¤Áø±¸ ´Éµ¿·Î 120-1(Ⱦ絿) °Ç±¹´ëÇб³º´¿ø